Wikidata

(Q63843237)

English

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

clinical trial

In more languages

Statements

short name
COMET-1 (English)
0 references
title
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100 (English)
0 references
country
Australia
0 references
Austria
0 references
Belgium
0 references
Canada
0 references
France
0 references
Germany
0 references
Republic of Ireland
0 references
Italy
0 references
Netherlands
0 references
Spain
0 references
Sweden
0 references
United Kingdom
0 references
start time
July 2012
0 references
end time
September 2014
0 references
number of participants
1,028
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63843237&oldid=1857505538"